Natalia G Karasseva

Title: Innovations by Natalia G Karasseva

Introduction

Natalia G Karasseva is a prominent inventor based in Columbia, MO (US). She has made significant contributions to the field of cancer research through her innovative work on peptides targeting the ErbB-2 receptor. With a total of 2 patents, her research has the potential to impact cancer imaging and therapeutic strategies.

Latest Patents

Karasseva's latest patents focus on the ErbB-2 receptor targeting peptide. The ErbB-2 receptor, a member of the tyrosine kinase type 1 family of receptors, has been implicated in many human malignancies. Bacteriophage display technology was employed to identify peptides that bound to the extracellular domain of human ErbB-2. The peptide KCCYSL, most frequently occurring in the affinity selected population, was chemically synthesized and characterized for its binding activities to the recombinant extracellular domain of ErbB-2. The synthetic peptide exhibits high specificity to ErbB-2 as well as to ErbB-1, another member of the ErbB family. Thus, this peptide can be employed in cancer imaging or therapeutic agent targeting to malignant cells expressing the ErbB-2 receptor.

Career Highlights

Karasseva is affiliated with the University of Missouri, where she conducts her research and develops her innovative ideas. Her work has garnered attention in the scientific community, particularly for its implications in cancer treatment.

Collaborations

One of her notable collaborators is Thomas P Quinn, who works alongside her at the University of Missouri. Their combined efforts contribute to advancing research in the field of cancer therapeutics.

Conclusion

Natalia G Karasseva's innovative work on ErbB-2 receptor targeting peptides showcases her commitment to advancing cancer research. Her contributions have the potential to lead to significant breakthroughs in cancer imaging and treatment strategies.